Get the Stockscreener App
2.86
11.18%
-0.36
Savara Inc stock is traded at $2.86, with a volume of 1.96M.
It is down -11.18% in the last 24 hours and up +4.38% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$3.22
Open:
$3.19
24h Volume:
1.96M
Relative Volume:
2.14
Market Cap:
$586.95M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-8.6667
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
-15.88%
1M Performance:
+4.38%
6M Performance:
-27.96%
1Y Performance:
-43.59%
1-Day Range:
$2.85
$3.33
1-Week Range:
$2.805
$3.558
52-Week Range:
$2.31
$5.11
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.86 | 586.95M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Wells Fargo & Company MN Has $182,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Sold by MetLife Investment Management LLC - Defense World
Analysts Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83 - Defense World
Barclays PLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World
Metric Deep Dive: Understanding Savara Inc (SVRA) Through its Ratios - DWinneX
Raymond James Financial Inc. Buys Shares of 259,798 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
A stock that deserves closer examination: Savara Inc (SVRA) - uspostnews.com
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire
Legal & General Group Plc Sells 12,613 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Savara Inc (NASDAQ:SVRA) Shares Purchased by Geode Capital Management LLC - Defense World
JMP maintains $10 target on Savara stock post-BLA submission By Investing.com - Investing.com Nigeria
Examining Savara Inc (SVRA) more closely is necessary - uspostnews.com
JMP maintains $10 target on Savara stock post-BLA submission - Investing.com
Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha
Savara Inc. Announces Equity Awards for New Employees - MSN
JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus
Savara Announces New Employment Inducement Grant - Enidnews.com
Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan
Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada
Savara to present aPAP treatment study at medical congresses - Investing.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan
259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World
Raymond James Financial Inc. Invests $798,000 in Savara Inc (NASDAQ:SVRA) - The AM Reporter
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):